Management Team

Niclas Stiernholm, PhD
Chief Executive Officer

Dr. Stiernholm's primary responsibilities at TTI include overseeing the company's strategic direction, executing business development plans and ensuring that the company's scientific programs continue to advance in good time. Dr. Stiernholm joined TTI from YM BioSciences where he acted as Executive Vice President and Chief Scientific Officer. While there, he played a significant role in the success of their Initial Public Offering (IPO) in 2002. Dr. Stiernholm began his industry career as a member of Allelix Biopharmaceuticals' business development office. He currently serves on several scientific and corporate boards of directors, including YM BioSciences, the Ontario Genomics Institute, AIM Therapeutics and Stem Cell Therapeutics. He received his Ph.D. in immunology from the University of Toronto, where he also completed his postdoctoral training.

Bob Uger, PhD
Vice President, Research and Development

Dr. Uger is responsible for developing and implementing the scientific direction of TTI, and oversees both internal product development and external research discovery programs. He also acts as the company’s scientific liaison with respect to global collaborations with academic and hospital research scientists. Dr. Uger joined TTI from Aventis Pasteur where he was a Senior Research Scientist involved in cancer vaccine research. He received his Ph.D. in immunology from the University of Toronto.

Penka Petrova, PhD
Director, Drug Development

Dr. Petrova is responsible for managing the company's formal drug development efforts, including all outsourced activities to CMOs and CROs. In addition, she continues to serve as the Head of Trillium's cell biology group and oversees all the company's in vivo studies. Dr. Petrova joined TTI from Prescient Neuropharma in 2003, where she held a Research Scientist position and was involved in identifying and characterizing novel proteins involved in neuroprotection. Dr. Petrova received her Ph.D. in Microbiology from Saarland University in Saarbruecken, Germany, where she also conducted her post doctoral studies.

James Parsons, CA, MA
Director, Finance & Administration

Mr. Parsons is a Chartered Accountant with an extensive background in the life sciences industry. From 2003 until present he has provided CFO and consulting services to both public and private life sciences companies. From 2000 to 2003 he was Vice President Finance and Administration at Lorus Therapeutics Inc. a TSX listed company. Mr. Parsons holds a Bachelor of Arts with Honours and a Master of Accounting from the University of Waterloo and is also a Certified Management Accountant.

Scott Duncan, BSc
Director, Patents and Licensing

Mr. Duncan is responsible for the strategic management of TTI's intellectual property (IP). He is also closely involved with license negotiations. He has over 20 years of experience in patents and licensing. He currently manages his own patent agency. Most recently, he has held the position of Director, Patents and Licensing at Allelix Biopharmaceuticals. He received his B.Sc. in Cell Biology from McMaster University in Hamilton, Ontario.